aleglitazar: Clinical Trials

6 completed, 1 withdrawn. 7 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	7	Completed 6, Withdrawn 1

Follow aleglitazar: new trials by email Literature Review of aleglitazar trials Research Report on aleglitazar

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study) Aleglitazar, Placebo - Diabetes Mellitus Type 2, Kidney Disease, Chronic	Phase 3	Withdrawn	Hoffmann-La Roche		2013-12-01	2016-11-02
A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy aleglitazar, placebo - Diabetes Mellitus Type 2	Phase 3	Completed	Hoffmann-La Roche	13	2013-06-01	2016-11-02
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy aleglitazar, metformin, placebo - Diabetes Mellitus Type 2	Phase 3	Completed	Hoffmann-La Roche	7	2013-05-01	2016-11-02
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy aleglitazar, placebo - Diabetes Mellitus Type 2	Phase 3	Completed	Hoffmann-La Roche	197	2012-12-01	2016-11-02
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities Placebo, aleglitazar - Cardiovascular Disease, Diabetes Mellitus Type 2	Phase 3	Completed	Hoffmann-La Roche	1999	2012-12-01	2016-11-02
A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy Placebo, aleglitazar - Diabetes Mellitus Type 2	Phase 3	Completed	Hoffmann-La Roche	196	2012-11-01	2016-08-11
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus Aleglitazar, Placebo - Diabetes Mellitus Type 2	Phase 3	Completed	Hoffmann-La Roche	7226	2010-02-01	2016-11-02

Conditions studied

Diabetes Mellitus, Type 2 (7)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Cardiovascular Diseases (1)  ·  Kidney Diseases (1)

Sponsors

Hoffmann-La Roche (7)

Countries

Mexico (4)  ·  United States (4)  ·  Argentina (3)  ·  China (3)  ·  Malaysia (3)  ·  South Korea (3)  ·  Australia (2)  ·  Canada (2)  ·  Colombia (2)  ·  Czechia (2)  ·  Germany (2)  ·  Hungary (2)  ·  Italy (2)  ·  Poland (2)  ·  Romania (2)

Results publications

PMID 25728612, PMID 24016490, PMID 24682069, PMID 29903845

NIH funding

2009 (1)